依帕司他治疗糖尿病周围神经病变的临床效果

Abstract
Figure/Table
References (21)
Related Citation (5)

Download: PDF (526 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the effects of Epalrestat in the treatment of diabetic peripheral neuropathy. Methods One hundred and twenty-three cases of patients with diabetic peripheral neuropathy admitted to Shunyi Hospital, Beijing Hospital of Traditional Chinese Medicine from February 2014 to December 2016 were selected and divided into control group, observation group and combined group by random table method, with 41 cases in each group. The control group was given Mecobalamin Tablets, the observation group was given Epalrestat Capsules, while the combined group was given Mecobalamin Tablets combined with Epalrestat Capsules. All three groups were treated for 12 weeks. Michigan neurological screening scale (MNSI) was used to evaluate the symptoms and signs of neuropathy. The electromyography was used to detect the nerve conduction velocity of exercise and sensory nerves in median nerve, nervus peroneus communis, ulnar nerve before and after treatment. The conditions of adverse reactions were recorded. Results After treatment, the scores of symptoms and signs of neuropathy of MNSI in the three groups were all lower than those before treatment (P ＜ 0.05), which of observation group and combined group were all lower than those of control group (P ＜ 0.05), while there were no statistically significant difference between observation group and combined group (P ＞ 0.05). After treatment, the nerve conduction velocity of exercise and sensory nerves in median nerve, nervus peroneus communis, ulnar nerve in the three groups were all faster than those before treatment (P ＜ 0.05), which of observation group and combined group were all faster than those of control group (P ＜ 0.05), while there were no statistically significant differences between observation group and combined group (P ＞ 0.05). There were no serious adverse reactions in the three groups. Conclusion Compared with Mecobalamin, Epalrestat can improve the symptoms, signs and nerve conduction velocity more effectively, and good safety, but combined treatments of the two drugs don′t show better efficacy.

Key words： Diabetic peripheral neuropathy Epalrestat Mecobalamin Nerve conduction velocity

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	GOU Chongyang1 ZHANG Jinchao2 ZHANG Xiuyuan1▲

Cite this article:

GOU Chongyang1 ZHANG Jinchao2 ZHANG Xiuyuan1▲. Clinical effect of Epalrestat in the treatment of diabetic peripheral neuropathy[J]. 中国医药导报, 2019, 16(19): 140-143.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2019/V16/I19/140

[1] 王杨，刘畅.依帕司他治疗糖尿病周围神经病变的疗效及机制[J].中国老年学杂志，2015，35（1）：93-95.doi：10.3969/j.issn.1005-9202.2015.01.045.
[2] 欧玉玲.甲钴胺联合前列地尔与依帕司他治疗糖尿病周围神经病变的疗效观察[J].广西医学，2013，35（12）：1681-1683.doi：10.11675/j.issn.0253-4304.2013.12.36.
[3] 黄云飞，黄春，宋玉玲，等.依帕司他联合前列地尔对糖尿病周围神经病变患者神经病变主觉症状、血管功能、神经功能的影响[J].中国现代医生，2014，52（11）：31-33，36.
[4] Hotta N，Kawamori R，Fukuda M，et al. Long-term clinical effects of epalrestat，an aldose reductase inhibitor，on progression of diabetic neuropathy and other microvascular complications：multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy [J]. Diabet Med，2012，29（12）：1529-1533. doi：10.1111/j.1464-5491.2012.03684.x
[5] 张晓兰，韩峰，郭晓珍，等.单唾液酸四己糖神经节苷脂钠联合依帕司他治疗糖尿病周围神经病变疗效观察[J].山东医药，2013，53（25）：54-55.doi：10.3969/j.issn.1002-266X.2013.25.021.
[6] 唐珊，梅红，温洪华，等.依帕司他联合贝前列素钠治疗糖尿病周围神经病变的疗效[J].江苏大学学报：医学版，2017，27（4）：305-308.doi：10.13312/j.issn.1671-7783.y170098.
[7] Maladkar M，Rajadhyaksha G，Venkataswamy N，et al. Efficacy，safety，and tolerability of Epalrestat compared to Methylcobalamine in patients with diabetic neuropathy [J]. Int J Diabetes Dev Ctries，2009，29（1）：28-34. doi： 10.4103/0973-3930.50712
[8] 中华医学会神经病学分会肌电图与临床神经电生理学组，中华医学会神经病学分会神经肌肉病学组.糖尿病周围神经病诊断和治疗共识[J].中华神经科杂志，2013， 46（11）：787-789.doi：10.3760/cma.j.issn.1006-7876. 2013.11.017.
[9] 胡泓.不同神经病变评分系统在无症状糖尿病周围神经病变筛查中的临床价值比较[D].杭州：浙江大学医学院，2010：1-48.
[11] 赵月蓉，侯碧玉，柳晨歌，等.依帕司他对2型糖尿病大鼠肝损伤的作用[J].首都医科大学学报，2017，38（2）：268-276.doi：10.3969/j.issn.1006-7795.2017.02.021.
[12] 宋佳佳，李素梅.α-硫辛酸联合依帕司他治疗糖尿病痛性神经病变的临床效果观察[J].中国糖尿病杂志，2016，24（9）：798-802.doi：10.3969/j.issn.1006-6187. 2016.09.007.
[13] 雷程灏，王尧.依帕司他在糖尿病并发症治疗中的作用[J].现代医学，2011，39（1）：112-116.doi：10.3969/j.issn.1671-7562.2011.01.040.
[14] 施君，张文川.糖尿病周围神经病变发病机制的研究进展[J].上海交通大学学报：医学版，2012，32（1）：116-119.doi：10.3969/j.issn.1674-8115.2012.01.024.
[15] 官常荣，朱英标，丁莉，等.鼠神经生长因子联合α-硫辛酸治疗糖尿病周围神经病变的临床观察[J].中国临床药理学杂志，2014，30（10）：892-894，900.doi：10. 13699/j.cnki.1001-6821.2014.10.006.
[16] 沈娟，曾辉，李连喜，等.振动感觉阈值（VPT）在糖尿病周围神经病变（DPN）中的诊断价值[J].复旦学报：医学版，2013，40（1）：31-37.doi：10.3969/j.issn.1672-8467. 2013.01.007.
[17] Li QR，Wang Z，Zhou W，et al. Epalrestat protects against diabetic peripheral neuropathy by alleviating oxidative stress and inhibiting polyol pathway [J]. Neural Regen Res，2016，11（2）：345-351. doi：10.4103/1673-5374. 177745.
[18] Hotta N，Kawamori R，Atsumi Y，et al. Stratified analyses for selecting appropriate target patients with diabetic peripheral neuropathy for long-term treatment with an aldose reductase inhibitor，epalrestat [J]. Diabet Med，2008，25（7）：818-825.doi：10.1111/j.1464-5491.2008. 02490.x
[19] 阮希成，蔡奕琪，林坚，等.甲钴胺、依帕司他、马来酸桂哌齐特治疗糖尿病周围神经病变的疗效观察[J].当代医学，2013，19（10）：113-114.doi：10.3969/j.issn.1009-4393.2013.10.083.
[20] 杨丹，鲍海萍，黄山，等.糖尿病周围神经病变患者的电生理检查结果及患病危险因素分析[J].中国糖尿病杂志，2016，24（6）：540-542.doi：10.3969/j.issn.1006-6187. 2016.06.011.
[20] 奚惠娟.依帕司他联合甲钴胺治疗糖尿病周围神经病变临床与神经电生理分析[J].实用临床医药杂志，2011， 15（24）：104-106.doi：10.3969/j.issn.1672-2353.2011. 24.037.
[21] 陈晓倩，欣冰，李杰，等.α-硫辛酸和依帕司他治疗糖尿病周围神经病变疗效观察[J].中国临床研究，2014， 27（1）：28-30.doi：10.13429/j.cnki.cjcr.2014.01.028.